Chromadex (CDXC) Lowered to “Sell” at BidaskClub

Chromadex (NASDAQ:CDXC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.

Other equities research analysts also recently issued reports about the stock. HC Wainwright set a $8.00 price target on shares of Chromadex and gave the company a “buy” rating in a report on Tuesday. Zacks Investment Research upgraded Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Tuesday, November 28th. Finally, ValuEngine downgraded Chromadex from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $7.50.

Shares of Chromadex (NASDAQ CDXC) traded up $0.49 during midday trading on Friday, reaching $5.44. 3,314,321 shares of the company’s stock were exchanged, compared to its average volume of 325,412. Chromadex has a 52 week low of $2.26 and a 52 week high of $7.24. The company has a quick ratio of 4.12, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market cap of $266.50, a P/E ratio of -38.85 and a beta of 1.37.

Chromadex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02). Chromadex had a negative net margin of 21.89% and a negative return on equity of 47.30%. sell-side analysts anticipate that Chromadex will post -0.15 EPS for the current year.

In related news, major shareholder River Ventures Ltd Champion acquired 731,707 shares of the business’s stock in a transaction on Friday, November 17th. The shares were purchased at an average price of $4.10 per share, for a total transaction of $2,999,998.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $6.19, for a total value of $361,496.00. The disclosure for this sale can be found here. 11.59% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of CDXC. Thompson Davis & CO. Inc. acquired a new position in shares of Chromadex in the 3rd quarter valued at about $128,000. Goldman Sachs Group Inc. increased its holdings in shares of Chromadex by 870.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock valued at $698,000 after purchasing an additional 163,817 shares during the period. Finally, Granite Investment Partners LLC increased its holdings in shares of Chromadex by 5.7% in the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock valued at $1,076,000 after purchasing an additional 13,599 shares during the period. Hedge funds and other institutional investors own 5.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Chromadex (CDXC) Lowered to “Sell” at BidaskClub” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/27/chromadex-cdxc-lowered-to-sell-at-bidaskclub.html.

Chromadex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply